CSL Behring Medical Expert Portal is a European webpage designed for healthcare professionals (HCPs) who are interested in serious and life-threatening conditions. Register and login to access the information on this webpage and to receive updates when new content becomes available. If you are interested in the relevant content for a specific country, please refer to the CSL Behring affiliate in your country to obtain relevant information. The medical and scientific information provided on this website is for informational purposes only and should not replace professional advice from a healthcare provider in your area. It is important that you always adhere to the regulations and guidelines relevant to your country.

Disclaimer: Due to compliance regulations, not all content of this webpage is intended for UK healthcare practitioners. If you would like to access UK specific materials on this site, please reach out to your local CSL Behring medical representative (medinfo@cslbehring.com) for assistance.

Disclaimer

CSL EXPERT HIVE

Symposia replays

Gene Therapy: A paradigm shift in haemophilia

Pathology:

Haemophilia A Haemophilia B

EAHAD 15th Annual Congress, February 2–4 2022 

Watch the full symposium video recording of the CSL Behring EAHAD satellite symposium held on February 1, 2022.

The symposium featured presentations from Giancarlo Castaman (Italy), Annette von Drygalski (USA), Michiel Coppens (The Netherlands) and Greta Mulders (The Netherlands) highlighting the current haemophilia treatment landscape and what the future holds for haemophilia care, including managing change and shifting mindsets for a new treatment paradigm. The presentations were followed by an interactive discussion section with the faculty and audience.

This information was developed for an EU audience. Please note that this webinar contains information on specific products and indications, including discussion of products in late-stage clinical trials which are not currently licenced. The Summary of Product Characteristics (SmPC) provided may vary depending on local approval in each country. Best efforts were undertaken by CSL Behring and congress sponsors to ensure compliance with EFPIA Code of Practice in line with the Joint Guidelines (IFPMA, EFPIA and PhRMA). However, you should review your local prescribing information and/or SmPC and consult directly with the local affiliate of CSL Behring to address any questions.